Literature DB >> 12791913

Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.

Marc Wirden1, Anne Simon, Luminita Schneider, Roland Tubiana, Luc Paris, Anne Genevieve Marcelin, Constance Delaugerre, Mayeule Legrand, Serge Herson, Gilles Peytavin, Christine Katlama, Vincent Calvez.   

Abstract

A 2-month interruption of only nonnucleoside reverse transcriptase inhibitors (NNRTIs) for patients carrying mutations associated with resistance to NNRTIs was followed by no change in either viral load or CD4 cell counts. These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12791913      PMCID： PMC156544          DOI： 10.1128/JCM.41.6.2713-2715.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Authors:  C Delaugerre; R Rohban; A Simon; M Mouroux; C Tricot; R Agher; J M Huraux; C Katlama; V Calvez
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

2.  The role of genotypic resistance testing in selecting therapy for HIV

Authors: 
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

3.  Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

Authors:  J L Casado; K Hertogs; L Ruiz; F Dronda; A Van Cauwenberge; A Arnó; I Garcia-Arata; S Bloor; A Bonjoch; J Blazquez; B Clotet; B Larder
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Authors:  L T Bacheler; E D Anton; P Kudish; D Baker; J Bunville; K Krakowski; L Bolling; M Aujay; X V Wang; D Ellis; M F Becker; A L Lasut; H J George; D R Spalding; G Hollis; K Abremski
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

8.  A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208.

Authors:  D Havlir; M M McLaughlin; D D Richman
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

9.  In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.

Authors:  J W Mellors; G E Dutschman; G J Im; E Tramontano; S R Winkler; Y C Cheng
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

10.  High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Authors:  D Havlir; S H Cheeseman; M McLaughlin; R Murphy; A Erice; S A Spector; T C Greenough; J L Sullivan; D Hall; M Myers
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226
View more
  3 in total

Review 1.  Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

Authors:  Ashley D Holec; Subhra Mandal; Pavan Kumar Prathipati; Christopher J Destache
Journal:  Curr HIV Res       Date:  2017       Impact factor: 1.581

2.  Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.

Authors:  D T Dunn; R L Goodall; P Munderi; C Kityo; M Ranopa; L Bacheler; M Van Houtte; C Gilks; P Kaleebu; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

3.  Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Authors:  Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.